Trading Report: Today, SciClone Pharmaceuticals Inc. (SCLN) Given Buy Rating at Maxim Group

Today, SciClone Pharmaceuticals Inc. (SCLN) Given Buy Rating at Maxim Group

SciClone Pharmaceuticals Inc. (NASDAQ:SCLN)‘s stock had its “buy” rating reissued by equities researchers at Maxim Group in a research note issued on Monday. They currently have a $14.00 price target on the specialty pharmaceutical company’s stock. Maxim Group’s price objective would indicate a potential upside of 35.27% from the stock’s current price.

The analysts wrote, “SciClone is a US-based specialty pharma company with its operating focus on the China pharmaceuticals market.””

SciClone Pharmaceuticals (NASDAQ:SCLN) traded up 0.49% during mid-day trading on Monday, hitting $10.25. The company’s stock had a trading volume of 307,761 shares. The company’s 50 day moving average is $9.76 and its 200-day moving average is $11.20. The stock has a market cap of $523.29 million, a P/E ratio of 14.64 and a beta of 1.65. SciClone Pharmaceuticals has a 52-week low of $7.36 and a 52-week high of $15.02.

In other news, Director Nancy T. Chang sold 25,040 shares of the business’s stock in a transaction on Tuesday, August 30th. The stock was sold at an average price of $10.30, for a total value of $257,912.00. Following the completion of the transaction, the director now owns 29,019 shares in the company, valued at $298,895.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Friedhelm Blobel sold 70,000 shares of the business’s stock in a transaction on Tuesday, November 22nd. The stock was sold at an average price of $10.22, for a total value of $715,400.00. Following the completion of the transaction, the chief executive officer now owns 102,637 shares of the company’s stock, valued at approximately $1,048,950.14. The disclosure for this sale can be found here. 7.63% of the stock is owned by insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Mason Street Advisors LLC acquired a new position in SciClone Pharmaceuticals during the second quarter valued at $127,000. GWM Advisors LLC acquired a new position in SciClone Pharmaceuticals during the third quarter valued at $104,000. Rational Advisors LLC acquired a new position in SciClone Pharmaceuticals during the second quarter valued at $140,000. Profund Advisors LLC acquired a new position in SciClone Pharmaceuticals during the second quarter valued at $141,000. Finally, Suntrust Banks Inc. boosted its position in SciClone Pharmaceuticals by 3.8% in the second quarter. Suntrust Banks Inc. now owns 11,938 shares of the specialty pharmaceutical company’s stock valued at $155,000 after buying an additional 432 shares in the last quarter. Hedge funds and other institutional investors own 75.68% of the company’s stock.

SciClone Pharmaceuticals Company Profile

Related posts

Leave a Comment